Shire Mexico – Dr. Raul Vivar, Head of Mexico / Central America and…
The general manager in charge of Mexico, Central America and the Caribbean is on board with the corporate mission of doubling Shire’s product sales to USD 10 billion by 2020…
As one of the world’s leading specialty biopharmaceutical companies, Shire has emerged as a company fully focused on a single purpose: to enable people with life-altering conditions to lead better lives. Today Shire provides treatments in the areas of Neuroscience, Rare Diseases, Gastrointestinal, and Internal Medicine. The company has a portfolio of specialist therapies marketed in over 50 countries worldwide and offices in 29 countries. The company has been present in Mexico since 2008 focusing on lysosomal storage diseases therapies. In the near future the company plans to provide a therapeutic option to patients with hereditary angioedema and start its neuroscience business unit with a product indicated for ADHD (attention deficit hyperactivity disorder).
Address:
Shire Pharmaceuticals Mexico S.A. de C.V Av. Paseo de los Tamarindos 90, Torre 1, Piso 7 Col. Bosques de las Lomas, Del. Cuajimalpa C.P. 05120, México DF MEXICO Tel: +52 (55) 5081 0120 Website: www.shire.com.mx
The general manager in charge of Mexico, Central America and the Caribbean is on board with the corporate mission of doubling Shire’s product sales to USD 10 billion by 2020…
Luisa Gutierrez, CEO at Medisi, explains the importance of helping get fast registration for high quality medtech products registrations and explains Medisi’s integral solutions for both the regulation and distribution…
Xavier Rams, General Director at Ferrer Mexico, explains the importance of aligning corporate strategy to public healthcare goals in order to succeed in the dynamic Mexican environment and showcases the…
Zurich Pharma was created with the vision of becoming a leader in the oncology segment at the international level. General manager and founder, Orlando Silva Fernandéz, discusses how state-of-the-art technology…
President and CEO of Grupo ENESA, Jaime Chico Pardo breaks down the private capital fund’s core investment pillars—centered on active management and driving long-term value—while elaborating on the flourishing opportunities…
Roberto Tapia-Conyer, General Director at the Carlos Slim Foundation, explains the unique position of the Foundation to develop and introduce innovation that could create breakthroughs in the National Healthcare System…
Cecilia Calderón, general director at Vigpharma, highlights how the national pharmacovigilance and technovigilance regulations have been evolving during the last five years as well as showcasing the added value of…
Joel Osorio, CEO & Founder Alejandro De La Parra, Co-Founder & Chief Operating Officer Alexa Jeppi, Co-Founder, RegenerAge Beauty & Health Ira Pastor, Board Member …
Representatives of Olivares, one of the leading law firms in Mexico, explain the evolving status of cannabis and narcotics for medicinal use in the country. A new Bill authorizing the…
M.S. Nagendra, Director General at Zydus Pharmaceuticals Mexico, explains the company’s unique business model, combining both branded generics and highly innovative medicines, while showcasing the strategic relevance of the Mexican…
Paulo de Resende, CEO of Laboratorios Grin-Lupin in Mexico, describes the current state of the Mexican pharmaceutical market and explains how the acquisition of Laboratorios Grin will help increase Lupin’s…
Enrique Carballido, general manager Mexico and Latin South America at Bio-Rad, showcases Bio-Rad’s offering in both diagnostics and life sciences and the crucial role of the entire industry in helping…
The founder and managing partner of the LatAm-based consultancy Oriundo, Paul Doulton discusses the company’s unique value offering—comprising both industry veterans and global associates to propel business development—while highlighting Mexico…
See our Cookie Privacy Policy Here
